<DOC>
	<DOCNO>NCT01461057</DOCNO>
	<brief_summary>This randomize , multicenter , open-label study evaluate two different dos pertuzumab combination Herceptin ( trastuzumab ) chemotherapy first-line treatment participant metastatic HER2-positive adenocarcinoma stomach gastroesophageal junction . Participants randomize 1:1 ratio two treatment arm . Participants Arm A receive pertuzumab load dose 840 mg Cycle 1 dose 420 mg Cycles 2-6 , participant Arm B receive pertuzumab 840 mg six cycle . Participants treatment arm receive trastuzumab , cisplatin , capecitabine .</brief_summary>
	<brief_title>A Study Pertuzumab Combination With Trastuzumab Chemotherapy Patients With HER2-Positive Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult participant , great equal ( &gt; = ) 18 age adenocarcinoma stomach gastroesophageal junction inoperable locally advanced metastatic disease , amenable curative therapy Measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) , v1.1 HER2positive tumor Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Life expectancy least 3 month Previous chemotherapy advance metastatic disease ( except ( prior adjuvant neoadjuvant therapy least 6 month enrollment study ) Lack physical integrity upper gastrointestinal tract malabsorption syndrome Active ( significant uncontrolled ) gastrointestinal bleeding Abnormal laboratory value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>